Please try another search
For the six months ended 30 June 2017, SciClone Pharmaceuticals, Inc. revenues increased 16% to $87.4M. Net income increased 89% to $26.8M. Revenues reflect China segment increase from $37.3M to $82.5M, Other Foreign segment increase from $1.7M to $4.9M. Net income benefited from China segment income increase from $13.3M to $35.1M. Basic Earnings per Share excluding Extraordinary Items increased from $0.29 to $0.52.
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 44.52 | 42.89 | 44.06 | 40.54 |
Gross Profit | 38.87 | 36.73 | 38.27 | 34.96 |
Operating Income | 12.32 | 14.24 | 7.41 | 10.45 |
Net Income | 12.19 | 14.6 | 6.41 | 10.12 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 277.61 | 253.48 | 241.9 | 233.36 |
Total Liabilities | 27.74 | 20.1 | 26.53 | 24.7 |
Total Equity | 249.87 | 233.38 | 215.37 | 208.66 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 20.34 | 5.63 | 34.53 | 30.96 |
Cash From Investing Activities | -0.67 | -0.07 | -3.37 | -2.86 |
Cash From Financing Activities | 3.18 | 1.34 | 1.86 | 0.61 |
Net Change in Cash | 22.93 | 6.95 | 32.99 | 28.71 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review